Announcements Trials
Browse Landscape

Phase

Phase 2 5Phase 3 1

Status

Active not recruiting 3Recruiting 2Not yet recruiting 1Completed 1

Sponsor Class

OTHER 5INDUSTRY 2

Study Type

Interventional 6Observational 1

Sponsor

Cancer Type

Gastrointestinal 7

Conditions

Carcinoma, Renal Cell 8Parkinson Disease 4, Autosomal Dominant Lewy Body 7Carcinoma, Hepatocellular 7Uterine Cervical Neoplasms 2von Hippel-Lindau Disease 1Vulvar Neoplasms 1Triple Negative Breast Neoplasms 1Stomach Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Small Cell Lung Carcinoma 1Penile Neoplasms 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Neuroendocrine Tumors 1Neoplasm Metastasis 1Hematologic Neoplasms 1Glioblastoma 1Esophageal Squamous Cell Carcinoma 1Esophageal Neoplasms 1Endometrial Neoplasms 1Colorectal Neoplasms 1Carcinoma, Transitional Cell 1Breast Neoplasms 1Biliary Tract Neoplasms 1Advanced Malignancies 1Advanced Gastric or Gastroesophageal Junction Adenocarcinoma 1

Interventions

Bevacizumab 11durvalumab 9atezolizumab 9Specimen Handling 9tremelimumab 8lenvatinib 7Nivolumab 6Magnetic Resonance Spectroscopy 5X-Rays 4Sorafenib 3Oxaliplatin 3Ipilimumab 3Fluorouracil 3tislelizumab 2sapanisertib 2relatlimab 2cabozantinib 2Surgical Procedures, Operative 2Radiation 2Leucovorin 2Immunotherapy 2Immunoglobulin G 2Doxorubicin 2Disulfides 2Carboplatin 2ulixertinib 1trifluridine tipiracil drug combination 1trastuzumab biosimilar HLX02 1trametinib 1sofosbuvir-velpatasvir drug combination 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

7 trials
RecentStart dateEnrollment
Carcinoma, Hepatocellular × lenvatinib × 30 days × Clear all
NCT07495579 2026-05-27

REVIVE

Asan Medical Center

Phase 2 Not yet recruiting
146 enrolled
Gastrointestinal

Carcinoma, Hepatocellular

NCT06187961 2026-05-22

CCGLC-011

Tongji Hospital

Phase 2 Active not recruiting
42 enrolled
Gastrointestinal

Carcinoma, Hepatocellular

NCT07493668 2026-05-22

FLEX-HCC

CHA University

Phase 2 Recruiting
80 enrolled
Gastrointestinal

Carcinoma, Hepatocellular

NCT04246177 2026-05-14

LEAP-012

Merck Sharp & Dohme LLC

Phase 3 Completed
479 enrolled
Gastrointestinal

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Hepatocellular

NCT07581769 2026-05-14

Radiomics Subtyping to Guide Surgery vs. Maintenance Therapy After HCC Downstaging

First Affiliated Hospital, Sun Yat-Sen University

Active not recruiting
500 enrolled
Gastrointestinal

Carcinoma, Hepatocellular

NCT07081633 2026-05-12

TREMENDOUS-2

AstraZeneca

Phase 2 Active not recruiting
114 enrolled
Gastrointestinal

Carcinoma, Hepatocellular

NCT07014150 2026-05-05

Neoadjuvant Therapy of Iparomlimab and Tuvonralimab Combined With Lenvatinib for Hepatocellular Carcinoma

Peking Union Medical College Hospital

Phase 2 Recruiting
33 enrolled
Gastrointestinal

Carcinoma, Hepatocellular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡